Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

High profile international goals have been set for the elimination of hepatitis B virus (HBV) infection as a public health threat by the year 2030. Developing and expanding equitable, accessible translational HBV research programmes that represent real-world populations are therefore an urgent priority for clinical and academic communities. We present experiences and insights by an expert interdisciplinary group focusing on barriers that impede adults living with HBV infection from participating in clinical studies. Our viewpoint describes barriers we have identified through working in a variety of settings across South Africa, including lack of education and awareness, experiences of stigma and discrimination, challenges for governance and data management, and a burden of complex morbidity. Through identifying these challenges, we propose solutions and interventions, highlight new approaches, and provide a framework for future research.

Original publication

DOI

10.1016/j.jve.2023.100317

Type

Journal article

Journal

J Virus Erad

Publication Date

03/2023

Volume

9

Keywords

Barriers, Clinical research, Elimination, Equity, Ethics, HBV, HBV, Hepatitis B Virus, HCV, Hepatitis C Virus, HCW, Healthcare Workers, HIV, Human Immunodeficiency Virus, Hepatitis B virus, LMIC, South Africa, TB, Tuberculosis, Trials, WHO, World Health Organization, eHealth, Electronic Health